Honokiol, a low molecular weight natural product, prevents inflammatory response and cartilage matrix degradation in human osteoarthritis chondrocytes

Journal of Orthopaedic Research

Volumn 32, Issue 4, 2014, Pages 573-580

  Chen, Ying Ju ^a   Tsai, Keh Sung ^b   Chan, Ding Cheng ^c   Lan, Kuo Cheng ^d   Chen, Cheng Feng ^e   Yang, Rong Sen ^b   Liu, Shing Hwa ^a,f  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^e Department of Dentistry   (Taiwan)

^f CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

chondrocyte; collagen II; honokiol; MMP 13; osteoarthritis

Indexed keywords

CHONDROCYTE; COLLAGEN II; HONOKIOL; MMP-13; OSTEOARTHRITIS;

AGED; ANTI-INFLAMMATORY AGENTS; BIPHENYL COMPOUNDS; CELL SURVIVAL; CHONDROCYTES; COLLAGEN TYPE II; DRUGS, CHINESE HERBAL; HUMANS; I-KAPPA B KINASE; LIGNANS; MAGNOLIA; MATRIX METALLOPROTEINASE 13; MIDDLE AGED; NF-KAPPA B; OSTEOARTHRITIS; SIGNAL TRANSDUCTION;

EID: 84893855866     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22577     Document Type: Article

References (35)

1. Goldring MB, Goldring SR., 2007. Osteoarthritis. J Cell Physiol 213: 626-634. (Pubitemid 350058254)
2. Fernandes JC, Martel-Pelletier J, Pelletier JP., 2002. The role of cytokines in osteoarthritis pathophysiology. Biorheology 39: 237-246. (Pubitemid 34626067)
3. Vincenti MP, Brinckerhoff CE., 2001. Early response genes induced in chondrocytes stimulated with the inflammatory cytokine interleukin-1 β. Arthritis Res 3: 381-388. (Pubitemid 33077119)
4. Goldring SR, Goldring MB., 2004. The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin Orthop Relat Res 427: S27-S36. (Pubitemid 39362798)
5. Ryu J, Treadwell BV, Mankin HJ., 1984. Biochemical and metabolic abnormalities in normal and osteoarthritic human articular cartilage. Arthritis Rheum 27: 49-57. (Pubitemid 14176536)
6. Largo R, Alvarez-Soria MA, Díez-Ortego I, et al. 2003. Glucosamine inhibits IL-1beta-induced NFκB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage 11: 290-298. (Pubitemid 36410882)
7. Hernandez-Diaz S, Garcia Rodriguez LA., 2001. Epidemiological assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med 110: 20S-27S. (Pubitemid 32155399)
8. Garcia Rodriguez LA, Hernandez-Diaz S., 2000. The epidemiology of myocardial infarction and heart failure among users of nonsteroidal anti-inflammatory drugs. Epidemiology 11: 382-387. (Pubitemid 30428929)
9. Nielsen GL, Sorensen HT, Larsen H, et al. 2001. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. Br Med J 322: 266-270. (Pubitemid 32178552)
10. Liou KT, Shen YC, Chen CF, et al. 2003. Honokiol protects rat brain from focal cerebral ischemia-reperfusion injury by inhibiting neutrophil infiltration and reactive oxygen species production. Brain Res 992: 159-166.
11. Lo YC, Teng CM, Chen CF, et al. 1994. Magnolol and honokiol isolated from Magnolia officinalis protect rat heart mitochondria against lipid peroxidation. Biochem Pharmacol 47: 549-553.
12. Chiang CK, Sheu ML, Hung KY, et al. 2006. Honokiol, a small molecular weight natural product, alleviates experimental mesangial proliferative glomerulonephritis. Kidney Int 70: 682-689.
13. Park J, Lee J, Jung E, et al. 2004. In vitro antibacterial and anti-inflammatory effects of honokiol and magnolol against Propionibacterium sp. Eur J Pharmacol 496: 189-195. (Pubitemid 39024332)
14. Kim BH, Cho JY., 2008. Anti-inflammatory effect of honokiol is mediated byPI3K/Akt pathway suppression. Acta Pharmacol Sin 29: 113-122.
15. Stanos SP., 2013. Osteoarthritis guidelines: a progressive role for topical nonsteroidal anti-inflammatory drugs. J Multidiscip Healthc 6: 133-137.
16. Weng TI, Wu HY, Kuo CW, et al. 2011. Honokiol rescues sepsis-associated acute lung injury and lethality via the inhibition of oxidative stress and inflammation. Intensive Care Med 37: 533-541.
17. Chen YJ, Wu CL, Liu JF, et al. 2010. Honokiol induces cell apoptosis in human chondrosarcoma cells through mitochondrial dysfunction and endoplasmic reticulum stress. Cancer Lett 291: 20-30.
18. Pyo MK, Lee Y, Yun-Choi HS., 2002. Anti-platelet effect of the constituents isolated from the barks and fruits of Magnolia obovata. Arch Pharm Res 25: 325-328.
19. Tsai SK, Huang SS, Hong CY., 1996. Myocardial protective effect of honokiol: an active component in Magnolia officinalis. Planta Med 62: 503-506. (Pubitemid 27006682)
20. Tsai SK, Huang CH, Huang SS, et al. 1999. Antiarrhythmic effect of magnolol and honokiol during acute phase of coronary occlusion in anesthetized rats: influence of L-NAME and aspirin. Pharmacology 59: 227-233. (Pubitemid 29473847)
21. Ishitsuka K, Hideshima T, Hamasaki M, et al. 2005. Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood 106: 1794-1800. (Pubitemid 41208596)
22. Wood DD, Ihrie EJ, Dinarello CA, et al. 1983. Isolation of an interleukin-1-like factor from human joint effusions. Arthritis Rheum 26: 975-983. (Pubitemid 13039816)
23. Goldring MB, Berenbaum F., 2004. The regulation of chondrocyte function by proinflammatory mediators: prostaglandins and nitric oxide. Clin Orthop 427: S37-S46. (Pubitemid 39362799)
24. Tetlow LC, Adlam DJ, Woolley DE., 2001. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage. Arthritis Rheum 44: 585-594. (Pubitemid 32234617)
25. Wu W, Billinghurst RC, Pidoux I, et al. 2002. Sites of collagenase cleavage and denaturation of type II collagen in aging and osteoarthritic articular cartilage and their relationship to the distribution of matrix metalloproteinase 1 and matrix metalloproteinase 13. Arthritis Rheum 46: 2087-2094.
26. Lewis EJ, Bishop J, Bottomley KM, et al. 1997. Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br J Pharmacol 121: 540-546. (Pubitemid 27226308)
27. Bruckner P, van der Rest M., 1994. Structure and function of cartilage collagens. Microsc Res Tech 28: 378-384. (Pubitemid 24222669)
28. Mitchell PG, Magna HA, Reeves LM, et al. 1996. Cloning, expression and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest 97: 761-768. (Pubitemid 26060542)
29. Burrage PS, Mix KS, Brinckerhoff CE., 2006. Matrix metalloproteinases: role in arthritis. Front Biosci 11: 529-543. (Pubitemid 43258162)
30. Firestein GS, Manning AM., 1999. Signal transduction and transcription factors in rheumatic disease. Arthritis Rheum 42: 609-621. (Pubitemid 29171980)
31. Tak PP, Firestein GS., 2001. NF-κB: a key role in inflammatory diseases. J Clin Invest 107: 7-11. (Pubitemid 32047405)
32. Shakibaei M, John T, Schulze-Tanzil G, et al. 2007. Suppression of NF-κB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: implications for the treatment of osteoarthritis. Biochem Pharmacol 73: 1434-1445. (Pubitemid 46452591)
33. Liacini A, Sylvester J, Li WQ, et al. 2002. Inhibition ofinterleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor κB (NF-κB) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol 21: 251-262. (Pubitemid 34497016)
34. Singh R, Ahmed S, Islam N, et al. 2002. Epigallocatechin-3-gallate inhibits interleukin-1β-induced expression of nitric oxide synthase and production of nitric oxide in human chondrocytes: suppression of nuclear factor κB activation by degradation of the inhibitor of nuclear factor κB. Arthritis Rheum 46: 2079-2086.
35. Roman-Blas JA, Jimenez SA., 2006. NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 14: 839-848. (Pubitemid 44138675)